Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.

Fiala O, Tkadlecová M, Buchler T, Kopecký J, Tomčová Z, Vočka M, Syčová-Milá Z, Študentová H, Matějů M, Savka A, Šlachtová E, Priester P, Králíček J, Spisarová M, Zemánková A, Lohynská R, Grmelová L, Obertová J, Stránský P Jr, Melichar B, Poprach A, Palacka P

Open source

DOI: 10.3389/fimmu.2026.1863009
Published: 2026
Container: Frontiers in immunology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1863009,
  title = {Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.},
  author = {Fiala O and Tkadlecová M and Buchler T and Kopecký J and Tomčová Z and Vočka M and Syčová-Milá Z and Študentová H and Matějů M and Savka A and Šlachtová E and Priester P and Králíček J and Spisarová M and Zemánková A and Lohynská R and Grmelová L and Obertová J and Stránský P Jr and Melichar B and Poprach A and Palacka P},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1863009},
  url = {https://doi.org/10.3389/fimmu.2026.1863009}
}

RIS

TY  - JOUR
TI  - Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.
AU  - Fiala O
AU  - Tkadlecová M
AU  - Buchler T
AU  - Kopecký J
AU  - Tomčová Z
AU  - Vočka M
AU  - Syčová-Milá Z
AU  - Študentová H
AU  - Matějů M
AU  - Savka A
AU  - Šlachtová E
AU  - Priester P
AU  - Králíček J
AU  - Spisarová M
AU  - Zemánková A
AU  - Lohynská R
AU  - Grmelová L
AU  - Obertová J
AU  - Stránský P Jr
AU  - Melichar B
AU  - Poprach A
AU  - Palacka P
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1863009
UR  - https://doi.org/10.3389/fimmu.2026.1863009
ER  -

APA

O, F., M, T., T, B., J, K., Z, T., M, V., Z, S., H, Š., M, M., A, S., E, Š., P, P., J, K., M, S., A, Z., R, L., L, G., J, O., Jr, S. P., B, M., A, P., & P, P. (2026). Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1863009

Source records

pubmed · retrieved 2026-09-26T01:40:46.393Z